New York, NY 19 May 2021: According to a new study published by Polaris Market Research, the global eClinical solutions market is anticipated to reach over USD 12,985 million by 2026. In 2017, the CTMS segment dominated the global market, in terms of revenue. In 2017, North America accounted for the majority share in the global eClinical solutions market.
Government organizations across the globe have implemented stringent guidelines to obtain error-free authentic clinical data due to the burgeoning number of clinical data research. EClinical data software facilitates processing of real-time data entries. Moreover, the need to process massive amount of data in the least possible time increases the adoption of these solutions.
The governments of various countries across the globe have sanctioned funds to promote clinical research of novels drugs. Increase in incidence of diseases across the globe has enforced government agencies to expedite the process of drug approval. The adoption of clinical data management systems has increased in the recent years to process the queueing molecules in the development phase of clinical research.
Technological advancements in eClinical software such as use of cloud computing to secure the data and improve accessibility across remote locations are expected to boost the market growth. Cloud based solution software dominated the global market in 2017, owing to the ease of delivery and convenience of upgrading to advanced versions. This segment has been gaining traction in the recent years, and is expected to grow at the fastest rate during the forecast period
Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/eclinical-solutions-market/request-for-sample
Several pharmaceutical organizations have deployed eClinical solution software to comply with the norms of the regulatory bodies for processing clinical data without errors and without any scope for manipulation. According to the ALCOA standard, the use of electronic clinical outcome assessments (eCOA) is essential in clinical trials, as these use smartphones, tablets, and personal computers to allow patients, clinicians, and their caregivers to directly report outcomes, which ensure highly productive data for better understanding of patient experience and faster approval process.
Among end users, the CROs segment is expected to grow at the fastest rate due to the ongoing trend of outsourcing clinical research operations to these third party organizations to save time and cost. As most of the drugs that have cleared Phase III clinical trials can be marketed under FDA norms with proper recommendations and guidelines through a new drug application (NDA), a majority of the drugs across the globe are in this phase of clinical research. Hence, most of the clinical data management systems were used for conducting phase III clinical trials.
The key players profiled in the report are Oracle Corporation, Parexel International Corporation, Medidata Solution, Inc., DataTrak International, Inc., CRF Health, OmniComm Systems, BioClinica Inc., eResearch Technology, eClinical Solutions, Inc., and PHT Corporation. The prominent players operating in the industry have adopted various strategies such as mergers and acquisition, product innovation and expansion, and R&D of innovative products.
To get Incredible Discounts on this Premium Report, Click At : https://www.polarismarketresearch.com/industry-analysis/eclinical-solutions-market/request-for-discount-pricing
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.
Contact Us:
Polaris Market Research
Phone: 1–646–568–9980
Email: [email protected]
The Spirulina Market is expected to grow at a CAGR of 10.3% from 2020-2030, according to a new research report by Next Move Strategy ConsultingSpirulina is a blue green algae with high nutrient content, usually consumed by human & animals.
It is also used as a complementary diet ingredient in aquaculture & poultry feeds owing to the presence of high protein & vitamin content.According to the report, growth in health consciousness among people and the rising demand for dietary supplements are major factors driving the spirulina market growth.
Additionally, high penetration of spirulina in industries such as cosmetics and pharmaceutical owing to the advantageous properties such as anti-aging, anti-wrinkles and othersare bringing changes in market tends.However, low stability & poor sustainability of spirulina derived colours is expected to restrict the market growth.Moreover, growth in research & development activities followed by untapped market opportunities in developing economies are anticipated to provide numerous opportunities to the market players in the coming few years.On the basis of type, spirulina market share is segmented into Arthrospira Platensis and Arthrospira Maxima.
Arthrospira Maxima dominates the global Spirulina market and will be the dominant throughout the forecasted period.On the basis of application, the Spirulina market is categorised into Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others.Food & Beverages segment is likely to develop significantly over the period of time owing to fast growing food & beverage industry.On the basis of drug formulation, the spirulina market is bifurcated into Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent.
Powder segment is expected to account for the major market share & dominate the market growth over the forecast period.North America dominates the spirulina market in terms of market size over the forecast period, owing to rising health consciousness among people.
Hansen Holding A/S, Algenol Biofuels Inc., Dongtai City Spirulina Bio-engineering Co., Ltd., Prolgae, Parry Neutraceuticals, Sensient Technologies Corporation, DDW Inc., Algatec and Naturex S.A.Browse key industry insights from the report, “Spirulina Market Size By Type (ArthrospiraPlatensis and Arthrospira Maxima) By Application (Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others), By Drug Formulation (Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent)Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, Indonesia, Malaysia, South Korea, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Kuwait), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2030” in detail along with the table of contents:Key Insights from the Spirulina Market Report:Asia Pacific is the fastest growing region in Spirulina market owing to the rising demand of spirulina from various industries such as cosmetics, food , healthcare and others and government initiatives to promote local spirulina production.The Food & Beverages segment dominates the market in terms of application and is expected to grow at a significant CAGR to maintain the lead till 2030.Some of the major players in the market are DIC Corporation, Cyanotech Corporation, Chr.
This report studies the global market size of Robotic Surgery Systems in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Robotic Surgery Systems in these regions.
This report also studies the global Robotic Surgery Systems market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
Market size by End User
Rest of Central & South America
The study objectives of this report are:
To study and analyze the global Robotic Surgery Systems market size (value & volume) by company, key regions, products and end user, breakdown data from 2013 to 2017, and forecast to 2025.
Latest Research Report on “Sports Medicine Products Market” Added by Analytical Research Cognizance which covers Market Overview, Future Economic Impact, Competition by Manufacturers, Supply (Production), & Consumption Analysis
This report studies the global market size of Sports Medicine Products Market in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Sports Medicine Products in these regions.
This report also studies the global Sports Medicine Products market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
Get Sample for Sports Medicine Products Market Report @ http://www.arcognizance.com/enquiry-sample/131077
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Market size by End User
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
New York, NY 18 May 2021: The global gene therapy market expected to reach USD 5.02 billion by 2028, according to a new study by Polaris Market Research.
The report “Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By Vector Type (Viral, Non-viral); By Approach (Gene Augmentation, Oncolytic Viral Therapy, Immunotherapy, Others); By Therapeutic Area; By Route of Administration; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The rising prevalence of chronic disorders including heredity and oncology diseases, rise in the number of clinical trials in the concerned arena, and increase in product approvals from regulatory agencies are few factors boosting the market growth.
The market is fragmented based on the therapy area, vector type, approach, route of administration, and region.
In terms of therapeutic area, the market is segmented into autoimmune disorders, cardiovascular diseases, dermatological disorders, genetic disorders, hematological disorders, metabolic disorders, muscle-related diseases, oncological disorders, ophthalmic diseases, and others.
Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/request-for-sample Based on the vector type, the industry is further bifurcated into viral and non-viral vectors.
According to recent Fact.MR study, the Bleach Precursor market will grow at 1.4% during 2018-2027 period.
The overall growth in the bleach precursor market is anticipated to remain sluggish, with demand for bleach precursor expanding at 1.4% CAGR in terms of volume during the forecast period 2018-2027.
The Fact.MR study largely attributes the projected growth to technological advancements in manufacturing techniques, and rising demand for products in the sector.An Expert Perspective According to Fact.MR experts, the growth of Bleach Precursor factors will remain key drivers to growth of the Bleach Precursor market.
Request to View Sample of Report @ https://www.factmr.com/connectus/sample?flag=S_id=2311A Real Insight Fact.MR promises to ready new investors in the world of digital age with information from key stakeholders in the industry, objective forecasts, and independent analysis of a wide range of viewpoints.
The company leverages information from key stakeholders of information including World Bank, the UNO, WHO, among others to tackle challenges of investing with due diligence, and reliability.
An Apt Forecast For the Bleach Precursor market, Fact.MR has considered 2013 as the base year for projections, while 2018-2027 period as the forecast period.
